An interventional study of ICG-NIR guided surgery in Stomach Neoplasm, sponsored by Ho Seok Seo. Completed at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Ho Seok Seo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 522 studies in Stomach Neoplasms with a site in Korea, Republic of — 77 open to participants now, 116 under way, 20 of them phase 3. Stomach Neoplasms · Korea, Republic of.
Among the 522 studies in Stomach Neoplasms with a site in Korea, Republic of, this one is the 123rd largest by enrollment of the 449 interventional ones that give a count, is one of 31 that started in 2022, is one of 104 with no phase, and was the 333rd registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →77 of the 522 studies in Stomach Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 20+
SK Life Science, Inc. · Sites in Korea, Republic of, United States
Ages 18+
Gyeongsang National University Hospital · Sites in Korea, Republic of
Ages 20–85
Dong-A ST Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
522 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 195 · Phase 3 96 · Phase 4 13
First in 2000; this study’s year is marked. 31 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 95 across the 449 interventional studies, 444 across the 71 observational. Of the 302 that completed or were terminated, 59 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
182 of 522 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ho Seok Seo as lead sponsor.
Ho Seok Seo has 1 study filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
25 of the studies in Stomach Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488611Phase 3Soonchunhyang University HospitalPROGAIN Trial in Gastric Cancer Surgery | 2027-02 |
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05620628Jeeyun LeePh2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | 2026-12 |
| NCT06767449Yonsei UniversityZolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer | 2026-12-01 |
Add all 25 to your calendar (.ics) → With an account.
Among the 522 studies in Stomach Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As the survival rate of patients with gastric cancer has increased, there has been a growing interest in interventions that improve postoperative quality of life. Therefore minimally invasive surgery or endoscopic resection has been performed much more frequently. However, adequate lymph node dissection is important as well. The aim of the study is to identify the feasibility of indocyanine green - near infra-red (ICG-NIR) guided sentinel lymph node dissection for the treatment of gastric cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ICG 0.5mg/ml x 0.5ml x 4 sites
Procedure: ICG-NIR guided surgery
ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
sensitivity and specificity
sensitivity and specificity of ICG-NIR guided lymph node dissection
Time frame: 1 month
Ran from Mar 2022 to primary completion in Aug 2022, 5 months.
Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's 5 months is below that.
Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Mar 2020 → Mar 2022, primary completion Aug 2020 → Aug 2022 and completion Dec 2020 → Dec 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.